OVIT Stock Recent News Oncovista Innovative Therapies I (OVIT)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Oncovista Innovative Therapies I (OVIT) 0.2385 $OVIT

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/snxwsx/acute_lymphocytic) has announced the addition of the "Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2013" report to their offering. 'Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). Scope - A snapshot of the global therapeutic scenario for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). - A review of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Johnson & Johnson Amgen Inc. Sanofi-Aventis Seattle Genetics, Inc. MedImmune LLC medac GmbH Gamida Cell Ltd. Bio-Path Holdings, Inc. Millennium Pharmaceuticals, Inc. Novartis AG Pfizer Inc. Incyte Corporation 4SC AG IMMUNOMEDICS, INC Ariad Pharmaceuticals, Inc. OncoVista Innovative Therapies, Inc. Jazz Pharmaceuticals, Inc. Portola Pharmaceuticals, Inc. Mundipharma International Limited MorphoSys AG Lipoxen PLC and many more... For more information visit http://www.researchandmarkets.com/research/sn...ymphocytic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
IMMU: 3.76 (-0.04), PTLA: 26.57 (-0.10), PFE: 30.34 (-0.08), INCY: 69.54 (-1.67), AMGN: 157.68 (-3.17), BMY: 57.95 (+0.15), JNJ: 108.16 (-0.91), BPTH: 3.00 (unch), JAZZ: 174.57 (+1.59), NVS: 93.95 (-0.43)

OTC Daily Alert Stock Watch - OncoVista Innovative Therapies, Inc. (OTCQB:OVIT)
WorldStockWire - Tue Aug 13, 6:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com

Colon Cancer - Pipeline Review, H2 2013 Gives Coverage of the Colon Cancer Pipeline on the Basis of Route of Administration and Molecule Type
M2 - Mon Aug 12, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/kfjngz/colon_cancer) has announced the addition of the "Colon Cancer - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Colon Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Colon Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Colon Cancer. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Colon Cancer. - A review of the Colon Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - AEterna Zentaris Inc. - Advenchen Laboratories, LLC - Affichem - Alethia Biotherapeutics Inc. - AlphaVax, Inc. - Cell Therapeutics, Inc. - Curis, Inc. - Cytokinetics, Inc - DEKK-TEC, Inc. - Eli Lilly and Company - Etubics Corporation - Five Prime Therapeutics, Inc. - Geistlich Pharma AG - ISA Pharmaceuticals B.V. - Isofol Medical AB - Kalos Therapeutics, Inc. - Lorus Therapeutics Inc - MabVax Therapeutics, Inc. - Northwest Biotherapeutics, Inc. - NovaLead Pharma Pvt. Ltd. - OncoMed Pharmaceuticals, Inc. - OncoVista Innovative Therapies, Inc. - Patrys Limited - PharmaMar, S.A. - Pharminox Limited - Pique Therapeutics - Tautatis Incorporated - Telik, Inc. - Transgene Biotek Ltd - Viventia Biotechnolo For more information visit http://www.researchandmarkets.com/research/kf...lon_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CYTK: 4.23 (-0.01), CRIS: 1.30 (-0.01), NWBO: 5.79 (-0.13), OMED: 20.17 (-0.68), LLY: 67.33 (-0.35), AEZS: 0.56 (-0.03)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Choate's: 68 Years of Community and Family Values

Updated Category News Views 3

Beyond Business: A Legacy of Giving Step into the world of Choate's, a renowned name in the Memphis area not just for its services in air conditioning, heating, plumbing, and electrical needs, but for its unwavering dedication to community service. For 68 years, this family-owned business has made its mark on the heart of Tennessee, spanning three generations and staying...

Continue Reading
Elevest Unveils MADE: Shaping Wealth for Athletes, Artists

Updated Category News Views 3

Turning Talent Into Tangible Wealth Ask any musician or athlete, and they'll tell you—riding those career highs is exhilarating, but financial stability can be a different ballgame. Here comes Elevest Capital with a fresh move meant to set the players right where many falter: long-term ownership. They're rolling out MADE, a new initiative focused on flipping that burst...

Continue Reading
Strategic Move: Chimney Collective Teams with Four Winds

Updated Category News Views 5

A Partnership Fueled by Legacy and Growth In the world of brick, mortar, and flue, a big play just unfolded. Chimney Collective, flexing its investment muscle, has hitched its wagon to Four Winds Chimney, a company that's carved out quite a niche in New York's chimney scene. We're not talking about a corporate takeover here; this is about putting money where growth and...

Continue Reading
Icebox Takes on Buckhead with Diamonds and Discounts

Updated Category News Views 4

So, Atlanta's Icebox Diamonds & Watches just dropped a news bomb that could shake up anyone with a taste for glitz and a wallet ready to act. This iconic jeweler, swinging its roots from a humble family biz to a global gem, is opening up its vault with an Inventory Reduction Sale starting October 9. And folks, it’s happening right at their Buckhead flagship showroom....

Continue Reading
Chianti Classico Showcases 2027 Vintages in Florence

Updated Category News Views 3

A Grand Reunion of the Black Rooster You're not just sipping wine at a garden party—you're diving into a historic event. Come March 1-2, 2027, Florence will again host the much-anticipated Chianti Classico Collection, uniting over 200 eager producers under the iconic vaults of Stazione Leopolda. This isn't just another stop on the wine circuit; it's a pilgrimage to the...

Continue Reading
Mastering Packaging Costs: Beyond the Box Price

Updated Category News Views 4

Peeling Back the Layers of Packaging Costs Packaging's a bit like an onion—every layer you peel back reveals another cost you didn’t see at first glance. Folks in the know, like Kyle Reger of Jamestown Container Companies, are flipping the script on how we approach packaging expenses. It's not just about snagging the cheapest box on the shelf anymore. There's a whole...

Continue Reading
Bill Evans Enhances Gateway's Wealth Management Expertise

Updated Category News Views 4

Welcome Aboard, Bill Evans Some days the financial world throws a gem your way, something worth more than a rat-race racehorse in a shattered stock rally. Meet Bill Evans, a seasoned professional stepping into the vibrant arena of Gateway Financial Partners. He’s put in 29 years around the investment block, and now he’s parking himself in Glastonbury, Connecticut, set...

Continue Reading
Armor Health Strengthens Corrections Care with New Leader

Updated Category News Views 3

Fresh Blood in Correctional Healthcare Talk about stepping up where it counts! Armor Health is shaking things up, bringing in Jill Bromley as their new Regional Behavioral Health Director. The name might not ring any bells for the average Joe, but in the world of correctional healthcare, it’s like they've just upgraded from a sedan to a sports car. Armor’s game here...

Continue Reading
ODL’s Impact Door System Wins 2026 Editors' Pick

Updated Category News Views 4

Award-Winning Entry: ODL's Latest Triumph In a world where first impressions count, ODL, Inc. sure knows how to leave a mark. Their Impact Rated Fiberglass Entry System with Keystone Frame Technology snagged a notable spot in the 2026 Best of Products Awards by Architect's Newspaper. Let me tell you, in the building biz, accolades like these are no small potatoes. To get...

Continue Reading
Boliden's Q3 2026 Results: What's on the Horizon?

Updated Category News Views 3

Boliden Ready to Reveal Q3 Numbers Mark it down, folks. Thursday, October 29, 2026, is the day when Boliden's big wigs will step up to the plate and lay their cards on the table about the company's performance over the last quarter. If you've got any skin in this mining powerhouse, you'll want a front-row seat—or at least a virtual one if you're dialing in from...

Continue Reading

Top 5 Most Recently Viewed Articles

Daversa Partners: Celebrating Recognition as a Top Employer

Updated Category News Views 236

Daversa Partners Recognized as One of the Best Employers Daversa Partners is proud to announce that its Miami office has achieved recognition as one of South Florida’s Best Places to Work for 2025. This significant honor highlights the firm’s unwavering commitment to fostering a workplace culture that champions teamwork and innovation. A Culture of Teamwork and...

Continue Reading
Qualcomm's Antitrust Case: EU Fine Reduction Explained

Updated Category News Views 90

Overview of Qualcomm's EU Antitrust Case Qualcomm Incorporated (NASDAQ: QCOM) has faced a pivotal moment in its ongoing legal conflict with the European Union regarding allegations of antitrust violations. Recent reports indicate that while the EU's second-highest court upheld most of the penalties imposed on Qualcomm, it did reduce the total fine slightly. The current...

Continue Reading
Constellation Brands Welcomes Paula Erickson to HR Leadership

Updated Category News Views 303

Paula Erickson Joins Constellation Brands as Chief HR Officer ROCHESTER, N.Y. -- Constellation Brands (NYSE: STZ), one of the leading beverage alcohol companies, has announced the appointment of Paula Erickson as the new Executive Vice President and Chief Human Resources Officer. This transition is set to take effect soon, and Erica will be a significant addition to the...

Continue Reading
Unlocking the Potential of Genetic Testing for C. auris Treatment

Updated Category News Views 180

Understanding Candida auris and Its Challenges Candida auris, a multidrug-resistant yeast, has emerged as a significant global health threat since its identification. This pathogen poses serious risks, particularly within healthcare settings. Its ability to resist multiple antifungal medications complicates treatment efforts, leading to severe patient outcomes, and it is...

Continue Reading
Qfin Holdings Reveals Strong Q3 Performance with Solid Metrics

Updated Category News Views 221

Qfin Holdings Reports Third Quarter Performance Qfin Holdings, Inc. (NASDAQ: QFIN; HKEx: 3660) has announced its unaudited financial results for the third quarter, showcasing significant developments in its operations. As a prominent AI-driven Credit-Tech platform in China, the company continues to adapt and excel in a dynamically changing financial landscape. Q3 2025...

Continue Reading